Bevacizumab for recurrent ependymoma.

ABSTRACT:

Background

Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies. Radiotherapy (RT) is commonly administered, but there is no standard chemotherapy. At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor. In recurrent glioblastoma, encouraging responses with bevacizumab have been observed.

Methods

In this Institutional Review Board-approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens. We determined radiographic response (Macdonald criteria), median time to progression (TTP), and median overall survival (OS; Kaplan-Meier method).

Results

There were 4 men and 4 women with a median age

SUBMITTER: Green RM 

PROVIDER: S-EPMC2788805 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature